ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity

ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity

Source: Pharmaceutical Technology

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, further results and analyses were presented from the SUMMIT trial. SUMMIT was the first trial in patients with heart failure with preserved ejection fraction (HFpEF) a… [4619 chars]

Read more